Introduction
Alzheimer’s disease, a progressive neurodegenerative disorder, affects millions of people worldwide. As we search for innovative solutions, Cognito Therapeutics has emerged with a novel therapy that holds promise for patients living with Alzheimer’s. Let’s delve into the science behind their groundbreaking Spectris™ headset and its potential impact. (Articles continues below video.)
Understanding Brain Waves and Alzheimer’s
Neurons communicate through electric signals, resulting in rhythmic brain activity known as “brain waves.” Among these waves, gamma waves play a crucial role in learning and memory. Unfortunately, in Alzheimer’s patients, gamma waves are altered, indicating impaired brain function1.
How Does Cognito’s Treatment Work?
Cognito’s therapy aims to evoke gamma wave activity through non-invasive visual and auditory stimulation. By using their Spectris™ headset, patients receive targeted sensory input at a frequency of 40 Hz. This therapy has shown promising results in clinical studies: (Article continued below video.)
- Phase 2 Trial: Alzheimer’s patients who used the headset for one hour daily over six months experienced a remarkable 80% reduction in functional decline, including memory loss and cognitive difficulties, compared to a placebo group2.
- Brain Atrophy Reduction: The therapy may also reduce white matter atrophy, protect axons, and potentially prevent damage to myelin and oligodendrocytes in Alzheimer’s patients3.
FDA Breakthrough Device Designation
Cognito’s treatment received the FDA Breakthrough Device Designation for addressing cognitive and functional symptoms associated with Alzheimer’s disease. This recognition underscores its potential as a disease-modifying therapy1. (Article continues below video.)
Expanding Possibilities
While initially focused on Alzheimer’s, Cognito aims to extend its approach to other indications. Their commitment to improving patients’ lives through neuronal activity modulation is commendable1.
Clinical Trial – Join the HOPE Study
Be part of the development of a new non-invasive wearable study device that delivers sensory stimulation and has the potential to slow the progression of mild to moderate Alzheimer’s disease, from the comfort of home. (Article continues below video…)
Cognito Therapeutics is currently enrolling patients for its pivotal study HOPE. For more information, visit www.hopestudyforad.com.
Conclusion
Cognito’s Spectris™ headset represents a beacon of hope for Alzheimer’s patients. By harnessing the power of gamma waves, this non-invasive therapy offers a path toward preserving brain structure, cognition, and function. As research continues, we eagerly await further breakthroughs in the fight against Alzheimer’s.
Remember, every step forward in Alzheimer’s research brings us closer to a brighter future for those affected by this challenging condition.
Would Cognito’s Spectris™ headset help prevent Alzheimer’s or is it only for those already diagnosed. Alzheimer’s runs in my family and I would like to do what I can to prevent it.
This sounds like an approach that inquired about by a Company in Switzerland that has a brain stimulation treatment that is approved in the E U but not by the U S FDA.
Are you aware of any progress from that company?
Does it work in Parkinson s Desease?